Other clinical trials in IPF that have assessed IL-13 antibodies have also demonstrated a lack of efficacy in this patient population, suggesting that IL-13 may not be an appropriate therapeutic target in IPF. The gene discussed is IL13; the disease is idiopathic pulmonary fibrosis.